Humacyte (HUMA) Non Operating Income (2020 - 2026)
Humacyte (HUMA) posted quarterly Non Operating Income of $11.3 million for Q1 2026, down 81.84% year-over-year from $62.3 million in Q1 2025, and up 87.6% quarter-over-quarter from $6.0 million in Q4 2025.
Humacyte (HUMA) Non Operating Income (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Non Operating Income for 7 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 81.84% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $16.3 million (down 51.12% YoY), while the FY2025 annual figure was $67.3 million, up 296.2% from the prior year.
- Non Operating Income advanced to $11.3 million in Q1 2026 per HUMA's latest filing, from $6.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $62.3 million in Q1 2025 and bottomed at -$27.2 million in Q2 2024.
- Historically, Non Operating Income has averaged $6.2 million across 5 years, with a median of $1.9 million in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 2574.99% — and 2023, when it plunged 848.68%.
- Humacyte's Non Operating Income stood at $17.1 million in 2022, then plunged by 93.7% to $1.1 million in 2023, then surged by 564.31% to $7.1 million in 2024, then slipped by 15.61% to $6.0 million in 2025, then surged by 87.6% to $11.3 million in 2026.
- Business Quant data shows HUMA's Non Operating Income at $11.3 million in Q1 2026, $6.0 million in Q4 2025, and $6.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.97 Bn | 132.12 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.64 Bn | 78.64 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 65.55 Bn | 60.37 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.26 Bn | 56.12 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.30 Bn | 37.20 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.66 Bn | 28.35 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.68 Bn | 10.29 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | -51.63 Mn |
| 10 | Humacyte | 154.07 Mn | 154.07 Mn | -825,000.00 | -9.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.81 Mn |
| Mar 31, 2026 | 11.32 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 6.88 Mn |
| Jun 30, 2025 | -7.93 Mn |
| Mar 31, 2025 | 62.32 Mn |
| Dec 31, 2024 | 7.15 Mn |
| Sep 30, 2024 | -8.97 Mn |
| Jun 30, 2024 | -27.16 Mn |
| Mar 31, 2024 | -5.32 Mn |
| Dec 31, 2023 | 1.08 Mn |
| Sep 30, 2023 | -1.37 Mn |
| Jun 30, 2023 | 4.03 Mn |
| Mar 31, 2023 | -14.46 Mn |
| Dec 31, 2022 | 17.07 Mn |
| Sep 30, 2022 | -1.79 Mn |
| Jun 30, 2022 | 55.40 Mn |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | 64.21 Mn |
| Sep 30, 2021 | -11.02 Mn |